Ecopipam Drug Asset Due Diligence Report 2026

This Ecopipam Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 3

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Ecopipam can convert its Small molecule drug profile and D1 receptor biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Ecopipam (query alias: ecopipam)
Modality / target	Small molecule drug; D1 receptor; D1 receptor antagonists
Highest global status	Phase 3
Originator	Merck Sharp & Dohme Corp.
Active developers	Emalex Biosciences, Inc., Merck Sharp & Dohme Corp.

The MCP disease footprint includes Tourette Syndrome, Lesch-Nyhan Syndrome, Restless Legs Syndrome. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06021522	Phase 3	Active, not recruiting	150	Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
NCT06194864	Phase 1	Completed	45	AUC0-inf of ecopipam when administered with itraconazole
NCT06669091	Phase 1	Completed	25	Cmax of ecopipam after administration of an ecopipam tablet in the fed state

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years

Phase 2; n=40; evaluation: not stated. Reported fields: YGTSS-TTS(Mean) = -3.4 Score on a scale (Standard Deviation, 5.8); YGTSS-TTS(Mean): Mean Difference (Final Values) = 0.2045(95% CI, -5.4871 to 1.2139), P-Value = <0.05; YGTSS-TTS(Mean) = -5.6 Score on a scale (Standard Deviation, 8.7)

Treatment of Restless Leg Syndrome (RLS) Augmentation With Ecopipam, a D1 Specific Antagonist

Phase 1/2; n=10; evaluation: not stated. Reported fields: IRLS mean at Baseline (Pre-intervention))(Mean) = 21.6 score on a scale (Standard Deviation, 7.89); IRLS mean at Baseline (Pre-intervention))(Mean) = 20.6 score on a scale (Standard Deviation, 6.5); -

A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Maintenance of Efficacy of Ecopipam in Children, Adolescents and Adults With Tourette's Disorder

Phase 3; n=216; evaluation: not stated. Reported fields: -; -; Time From Randomization to Relapse in Participants Greater Than and Equal to (>=) 6 and Less Than (<) 18 Years During the Double-Blind R/WD(Median) = 4.0 weeks (95% Confidence Interval, 2.4 - 6.1)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Ecopipam addresses Tourette Syndrome, Lesch-Nyhan Syndrome, Restless Legs Syndrome. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2026-04-29	Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy	Phase 3	US$700.0M upfront; US$200.0M milestones; US$900.0M stated total
2008-11-10	Psyadon Pharmaceuticals, Inc. Announces $8M Series A-1 Financing and In-License of Ecopipam from Schering Corporation	Clinical	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Method of providing ecopipam therapy to a patient”. The milestone feed surfaced a patent-application signal described as “Solid state form of ecopipam hydrobromide salt”. The milestone feed surfaced a patent-application signal described as “Application of dopamine D1 receptor antagonist SCH39166 in preparation of medicine for treating ocular pathological angiogenesis”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO